PPARGC1A and Dravet syndrome: All these evidences support the hypothesis that targeting mitochondrial dysfunction in DS could help to counteract cognitive impairment and that pharmacologically induced transcriptional activation of the PGC-1α pathway is expected to exert neuroprotective effects.